We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Paris to Host International Biology Days

By Biotechdaily staff writers
Posted on 13 Sep 2005
Paris (France) will host the 50th anniversary of the International Biology Days (JIB, Journees Internationales de Biologie) from November 3-5, 2005. More...
More than 8,000 visited the event in 2004, which had foreign participation of 15% and 147 exhibitors.

Biomedical engineers, laboratory assistants, and technicians convene to learn about the latest developments in their profession and the impact of new technologies on their specialty. On this jubilee anniversary, there will be a retrospective exhibition of devices that illustrate 50 years of technologic progress in medical biology. It all began in 1953 as a training day on medical analyses for interested pharmacists and then grew into the most important annual assembly of clinical biologists in Europe. Italy will be honored this year for its proactive approach of advancement and interchange with other European countries. For the first time, part of the scientific program will be held in English.

The conference will open with a session on oxidative stress markers. Other sessions will deal with proteomics, allergy research, standardized specifications of laboratory analyzers, and dosage of carotenoids. The second part of the program will highlight the diagnostic approach in mycology, the threat of multi-resistant bacteria, anticoagulation treatment clinics, the place of liquid-based smear in cervix testing, and the detection of the Papilloma virus by polymerase chain reaction (PCR) in cervical cancer screening. The Café Scientifique, a forum for the exchange of views on current topics, will enhance dialogues between specialists and professionals on themes of interest and topics related to biology.

The conference is sponsored by the Societe Francaise de Biologie Clinique (SFBC) and the Institute of Health and Medical Research (INSERM, Paris, France). Further details on the conference are available on the JIB website.




Related Links:
JIB

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Aspiration System
VACUSAFE
New
HPV Test
Allplex HPV28 Detection
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.